Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119992) titled 'Study on the efficacy and safety of large-split radiotherapy combined immunotherapy for primary liver cancer combined with Vp3-Vp4 with or without hepatic vein cancer embolus' on March 6.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The First Affiliated Hospital of Henan Medical University

Condition: HCC

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-03-15

Target Sample Size: Experimental group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=309340

Published by HT Digital Content Service...